Enlightenment Mental Health is working on developing partnerships with Biotech and Technology companies to assist in the early pre-clinical stage development of novel therapeutics for treatment of Mental Illnesses.
We shall pursue therapeutic discovery of both, synthesized and naturally based Psychedelic compounds.
Our Discovery strategy allows us to collaborate with Biotechnology partners to help us scale our drug discovery in early stages.
The Model leverages the Laboratory infrastructure of our partners without the need for capital infrastructure investment.
Our goal to create a Portfolio of Intellectual Property of Early-Stage Novel Psychedelic Molecular Discoveries that can be potentially commercialized by licensing.
We have entered into a preliminary agreement with Polaris qb, a drug discovery company focused on utilizing Quantum Computing, Artificial Intelligence (Ai) and Machine Learning (ML) to speed drug discovery & formulation development process. Our goal is to develop a Psilocybin based therapeutic compound.
We have entered into a preliminary agreement with PsyRX, an Israeli Government Licensed Biotech Company with Labs at Hebrew University, Tel Aviv. Developing Psychedelic Organic Compounds for Psilocybin & Ibogaine.
Receptor(s) Targeting. Psilocybin Impacts the Serotonin Receptors. Diagnosis: Serotonin Receptors(s)